Lung Data For Roche’s PD-L1 Atezolizumab In Line With PD-1 Family
Executive Summary
Lancet editorial highlights similarities in results for PD-L1 inhibitor atezolizumab with Bristol’s Opdivo and Merck’s Keytruda, despite use of different biomarker tests.